Advanced Enzyme Technologies net sales remained flat at Rs 110.26 crore for quarter ended Mar20. The company operating margins decreased 80 bps to 44.2% leading 2% decrease in operating profits to Rs 48.7 crore.
Other income stood at Rs 1.84 crore compared to Rs 2.64 crore. Interest cost was Rs 69 lakh compared to Rs 58 lakh. Depreciation rose 26% to Rs 6.65 crore. PBT was down 7% to Rs 43.2 crore.
Tax expenses were down 19% to Rs 10.52 crore owing to which the company's net profit reported was down 2% to Rs 32.68 crore. Further considering minority interest, Bottomline of the company was down 3% to Rs 31.33 crore.
In March 2020, the World Health Organisation declared COVID-19 to be a pandemic and several restrictions have been imposed by the Governments across the globe on the travel, goods movement and transportation considering public health and safety measures. Considering the Company's/ Group's products are classified as an ‘essential commodity', management believes that the impact of the pandemic may not be significant. As of today, production facilities remain operational, following enhanced internal safety guidelines. Management has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the company has sufficient resources to continue as a going concern.
Consolidated performance for the year ended Mar20
For year ended Mar20, net sales rose 6% to Rs 443.99 crore. The company operating margins increased 240 bps to 45.6%. As a result operating profits rose 11% to Rs 202.33 crore.
Other income rose 12% to Rs 5.64 crore. Interest cost was down 22% to Rs 3.04 crore. Depreciation rose 22% to Rs 25.78 crore. PBT was up 11% to Rs 179.16 crore.
The effective tax rate decreased to 25.7% from 28.4% owing to which the company's net profit rose 15% at Rs 133.05 crore. Further considering minority interest, Bottomline of the company fell 16% to Rs 129.29 crore.
The scrip is currently trading at Rs 151
|